US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PIMCO Municipal Income Fund II

7.62

+0.10001.33%

Post-market: 7.60-0.0200-0.26%16:05 EDT

Volume:115.19K

Turnover:875.75K

Market Cap:506.42M

PE:44.61

High:7.63

Open:7.63

Low:7.55

Close:7.52

Loading ...

Overview Company News Filings

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

PIMCO Closed-End Funds Announce Proposed Reorganizations

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Australian Prudential Regulator's Reinsurance Reforms Could Benefit Insurers over the Medium Term, Fitch Says

MT Newswires Live

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024

PIMCO Municipal Income Fund II declares $0.0395 dividend

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PML/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PML","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PML\",,,,,undefined,":{"symbol":"PML","market":"US","secType":"STK","nameCN":"PIMCO Municipal Income Fund II","latestPrice":7.62,"timestamp":1745611200000,"preClose":7.52,"halted":0,"volume":115186,"hourTrading":{"tag":"盘后","latestPrice":7.6,"preClose":7.62,"latestTime":"16:05 EDT","volume":203,"amount":1542.86,"timestamp":1745611514139},"delay":0,"floatShares":0,"shares":66459710,"eps":0.170814,"marketStatus":"Market Closed","change":0.1,"latestTime":"04-25 16:00:00 EDT","open":7.63,"high":7.63,"low":7.55,"amount":875749.96411,"amplitude":0.010638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.170814,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":7.52,"dividendRate":0.062205,"postHourTrading":{"tag":"盘后","latestPrice":7.6,"preClose":7.62,"latestTime":"16:05 EDT","volume":203,"amount":1542.86,"timestamp":1745611514139},"volumeRatio":0.5753333789408384},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PML\",,,,,undefined,":{"symbol":"PML","floatShares":0,"roa":"2.48%","roe":"0.09%","lyrEps":0.676799,"volumeRatio":0.5753333789408384,"shares":66459710,"dividePrice":0.474,"high":7.63,"amplitude":0.010638,"preClose":7.52,"low":7.55,"week52Low":7.12,"pbRate":"0.89","psRate":"11.07","week52High":9.52,"institutionHeld":0.1804,"latestPrice":7.62,"eps":0.170814,"divideRate":0.062205,"volume":115186,"delay":0,"ttmEps":0.170814,"open":7.63,"prevYearClose":8.09,"prevWeekClose":7.52,"prevMonthClose":8.1,"prevQuarterClose":8.1,"fiveDayClose":7.52,"twentyDayClose":8.04,"sixtyDayClose":8.34},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PML\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526718557","title":"TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526718557","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526718557?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:30","pubTimestamp":1744284600,"startTime":"0","endTime":"0","summary":"NEW YORK, April  10, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI (ublituximab-xiiy) in patients with relapsing for","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/10/3059147/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","LU2347655156.SGD","TGTX","BK4135","LU1989772840.SGD","PML","BK4090","LU0971096721.USD","TG","BK4581","LU0314104364.USD","LU2271345857.HKD","BK4107","LU0267386448.USD","AFG","BK4534","LU1668664300.SGD","BK4153","LU1162221912.USD","LU0158827781.USD","LU1074936037.SGD","LU1732799900.SGD","LU2111349929.HKD","LU2028103732.USD","LU0795875169.SGD","IE00BZ1G4Q59.USD","LU2133065610.SGD","LU0006306889.USD","LU2023251221.USD","LU0158827948.USD","LU2089283258.USD","BK4127","LU1548497426.USD","LU1720051017.SGD","BK4516","LU0320765646.SGD","BK4588","BK4117","LU1363072403.SGD","BK4139","LU2357305700.SGD","BK4201","LU1732800096.USD","CNS","LU0098860793.USD","LU2089284900.SGD","LU1989772923.USD","LU0106261372.USD","IE00BKVL7J92.USD","LU0225283273.USD"],"gpt_icon":0},{"id":"2525141570","title":"TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals","url":"https://stock-news.laohu8.com/highlight/detail?id=2525141570","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525141570?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:30","pubTimestamp":1744025400,"startTime":"0","endTime":"0","summary":"NEW YORK, April  07, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056593/8790/en/TG-Therapeutics-Announces-Two-Publications-Highlighting-BRIUMVI-in-Medical-Journals.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","LU0158827948.USD","BK4127","BK4585","LU1363072403.SGD","CNS","LU1732800096.USD","LU2357305700.SGD","LU0971096721.USD","LU2089283258.USD","PML","LU0006306889.USD","BK4516","LU0267386448.USD","LU1720051108.HKD","BK4504","LU0314104364.USD","TG","LU2089284900.SGD","LU0106261372.USD","BK4135","IE00BKVL7J92.USD","BK4201","LU0795875086.SGD","LU1162221912.USD","LU1732799900.SGD","BK4090","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1548497426.USD","LU0158827781.USD","LU2347655156.SGD","LU0106831901.USD","BK4588","LU1074936037.SGD","BK4581","LU0320765646.SGD","TGTX","EC","LU1989772840.SGD","BK4139","LU1989772923.USD","BK4534","LU0225283273.USD","LU2028103732.USD","LU1668664300.SGD","LU0098860793.USD","LU2111349929.HKD","LU0795875169.SGD","BK4153"],"gpt_icon":0},{"id":"2525030730","title":"PIMCO Closed-End Funds Announce Proposed Reorganizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2525030730","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525030730?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:33","pubTimestamp":1743798780,"startTime":"0","endTime":"0","summary":"NEW YORK, April 04, 2025  -- The Board of Trustees of each of the following funds has approved the following proposals to reorganize the PIMCO closed-end municipal funds , subject to the various shareholder approvals and other contingencies described below:. National Mergers: PIMCO Municipal Income Fund  and PIMCO Municipal Income Fund III  with and into PIMCO Municipal Income Fund II ;New York Mergers: PIMCO New York Municipal Income Fund  and PIMCO New York Municipal Income Fund III  with and into PIMCO New York Municipal Income Fund II ; and. Following the Mergers, each Acquiring Fund will continue to be managed in accordance with its existing investment objective and strategies:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-announce-203300996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PYN","PMF","PZC","PNF","PNI","PCQ","PMX","PCK","PML"],"gpt_icon":0},{"id":"2524182362","title":"UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE","url":"https://stock-news.laohu8.com/highlight/detail?id=2524182362","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524182362?lang=en_us&edition=fundamental","pubTime":"2025-04-04 03:35","pubTimestamp":1743708900,"startTime":"0","endTime":"0","summary":"Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo. UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in the MITIGATE Trial. Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD,IgG4-RD and gMG. THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Amgen  announced today that the U.S. Food and Drug Administration  has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease . IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine's potential to benefit patients.The approval of UPLIZNA for IgG4-RD is supported by data from the MITIGATE trial, the first ra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-now-first-193500981.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-now-first-193500981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1803068979.SGD","BK4543","LU1551013342.USD","BK4097","LU0265550946.USD","BK4608","LU0889565833.HKD","LU1917777945.USD","LU1951200564.SGD","BK4607","BK4585","BK4599","LU1057294990.SGD","IE0002141913.USD","LU0943347566.SGD","LU0265550359.USD","LU1983299246.USD","LU2468319806.SGD","BK4503","NOW","IS","BK4139","BK4534","LU2023250843.SGD","LU0353189680.USD","FOR","IE00B4R5TH58.HKD","LU0348723411.USD","LU1061106388.HKD","LU1989764748.USD","LU0672654240.SGD","LU0708995401.HKD","LU0689472784.USD","IE00BMPRXN33.USD","LU0320765059.SGD","BK4528","PML","LU1323610961.USD","LU2286300806.USD","BK4613","LU2087625088.SGD","LU1988902786.USD","LU0289739699.SGD","LU2458330243.SGD","LU0316494557.USD","LU2125909247.SGD","LU1551013425.SGD","AMGN","LU0889565916.HKD","LU0058720904.USD"],"gpt_icon":0},{"id":"2519183454","title":"UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS","url":"https://stock-news.laohu8.com/highlight/detail?id=2519183454","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519183454?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:00","pubTimestamp":1741870800,"startTime":"0","endTime":"0","summary":"Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing*. The Phase 3 MINT trial, which was a randomized-control trial, evaluated UPLIZNA in muscle-specific kinase autoantibody-positive  and AChR+ gMG patients, with the MuSK+ group followed for 26 weeks and the AChR+ group followed for 52 weeks. The trial demonstrated continued improvement in efficacy of UPLIZNA compared to placebo  as measured by the change in baseline of Myasthenia Gravis Activities of Daily Living  score in the AChR+ subpopulation through week 52. Among the AChR+ patients in the UPLIZNA group, 72.3% had a ≥3 point improvement in the MG-ADL score, compared to 45.2% in placebo.1. Change from baseline in the Quantitative Myasthenia Gravis  score was also greater for patients in the UPLIZNA group as compared to placebo at Week 52 . Among the AChR+ patients in the UPLIZNA group, 69.2% improved by ≥3 points in the QMG score, compared to 41.8% in the placebo group.1. \"I'm looking forwa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-significantly-improves-130000205.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-significantly-improves-130000205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PML","BK4566","LU1023059063.AUD","LU0289739699.SGD","LU1057294990.SGD","BK4533","LU1061106388.HKD","MINT","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","BK4581","BK4599","LU0320765992.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","AMGN","LU0058720904.USD","LU2112291526.USD","BK4550","IE00BJT1NW94.SGD","BK4534","BK4139","LU0109394709.USD","IE00B4R5TH58.HKD","LU0868494617.USD","BK4178","BK4588","LU1571399168.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2242652126.USD","LU1983299246.USD","SG9999001440.SGD","BK4585","LU2242646821.SGD","AAN"],"gpt_icon":0},{"id":"2517828574","title":"TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517828574","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517828574?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:30","pubTimestamp":1741350600,"startTime":"0","endTime":"0","summary":"NEW YORK, March  07, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI (ublituximab-xiiy) data in patients wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038884/8790/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","BK4504","LU0314104364.USD","LU0971096721.USD","LU1720051017.SGD","AFG","LU2023251221.USD","LU1668664300.SGD","BK4135","LU1989772840.SGD","LU2357305700.SGD","IE00BKVL7J92.USD","LU1989772923.USD","BK4585","LU2111349929.HKD","LU1548497426.USD","LU2347655156.SGD","LU1363072403.SGD","LU1732800096.USD","IE00BZ1G4Q59.USD","BK4090","BK4139","BK4534","BK4117","BK4588","LU2028103732.USD","BK4127","CNS","TGTX","LU0225283273.USD","LU2089284900.SGD","LU0158827781.USD","LU0267386448.USD","LU0320765646.SGD","PML","EC","BK4516","LU1074936037.SGD","LU0006306889.USD","LU0912757837.SGD","LU2133065610.SGD","LU1720051108.HKD","BK4153","TG","LU2089283258.USD","LU1162221912.USD","LU0106261372.USD","LU0158827948.USD","BK4107","LU0098860793.USD"],"gpt_icon":0},{"id":"2516327660","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2516327660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516327660?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:22","pubTimestamp":1741044120,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of January 31, 2025:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-232200478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PMX","STRK","BK4596","BK4588","PCM","PCQ","PDX","PNI","PCK","PDO","PGP","PDI","PNF","BK4585","PHK","PCN","PML","RCS","BK4600","BK4595","PZC","BK4023","PMF","PTY","BK4516","PAXS","PFN","PYN","PFL"],"gpt_icon":1},{"id":"2514099448","title":"TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099448?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:30","pubTimestamp":1740659400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb.  27, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial eval","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033752/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-in-Multiple-Sclerosis-at-the-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-Annual-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0158827781.USD","BK4588","BK4504","LU0795875086.SGD","LU2089283258.USD","LU2271345857.HKD","BK4090","CNS","LU1720051017.SGD","BK4179","IE00BKVL7J92.USD","LU1074936037.SGD","BK4201","LU1548497426.USD","LU2357305700.SGD","LU2028103732.USD","PML","BK4534","LU0098860793.USD","LU0225283273.USD","LU1720051108.HKD","LU0267386448.USD","LU0795875169.SGD","TG","LU2111349929.HKD","LU0912757837.SGD","LU1668664300.SGD","TGTX","BK4135","BK4139","LU2023251221.USD","BK4127","FET","LU0006306889.USD","EC","LU0106831901.USD","LU0106261372.USD","LU1989772923.USD","LU1162221912.USD","LU2089284900.SGD","BK4153","LU2133065610.SGD","LU0971096721.USD","LU1732800096.USD","BK4581","LU1732799900.SGD","LU1989772840.SGD","BK4585","LU0158827948.USD"],"gpt_icon":0},{"id":"2508175053","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175053","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175053?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:51","pubTimestamp":1738619460,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of December 31, 2024:. Annualized current distribution rate expressed as a percentage of Market Price as of 12/31/2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-215100530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PMX","PCM","PCQ","PDX","PNI","PCK","PDO","PGP","PDI","PNF","PHK","PCN","PML","RCS","PZC","PMF","PTY","PAXS","PFN","PYN","PFL"],"gpt_icon":0},{"id":"2504547451","title":"CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2504547451","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504547451?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:00","pubTimestamp":1737115200,"startTime":"0","endTime":"0","summary":"Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone. First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US. WILMINGTON, Del., January 17, 2025----AstraZeneca’s CALQUENCE  in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma  who are ineligible for autologous hematopoietic stem cell transplantation.The approval was granted by the Food and Drug Administration  after securing Priority Review. It was based on results from the ECHO Phase III trial which were presented at the European Hematology Association 2024 Congress.Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: \"With today’s approval, CALQUENCE provides a critical new treatment option to mantle cell lymphoma patients in the US, with CALQUENCE proven to deliver nearly one and a h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calquence-acalabrutinib-plus-chemoimmunotherapy-approved-120000864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4568","IE0009354923.USD","BK4588","LU0545562505.USD","BNTX","HSCT","BK4226","LU2456880835.USD","LU2462157665.USD","PML","BK4007","LU0320765992.SGD","LU0889565916.HKD","AZN","BK4106","BK4139","LU1228905540.USD","BK4535","LU0390134368.USD","BK4548","LU1228905037.USD","LU2236285917.USD","IE0034235188.USD","LU2417539215.USD","BR","ORR","LU0109394709.USD","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2500900549","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2500900549","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500900549?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:55","pubTimestamp":1735854900,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of November 30, 2024:. Annualized current distribution rate expressed as a percentage of NAV as of 11/30/2024. Annualized current distribution rate expressed as a percentage of Market Price as of 11/30/2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-215500914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PDI","PMX","PNF","PAXS","PZC","PGP","PNI","PCN","PYN","PTY","PFN","PCM","PDX","PCQ","PFL","PHK","PML","PDO","RCS","PCK","PMF"],"gpt_icon":1},{"id":"2490173091","title":"Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490173091","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490173091?lang=en_us&edition=fundamental","pubTime":"2024-12-09 00:00","pubTimestamp":1733673600,"startTime":"0","endTime":"0","summary":"CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting. CALQUENCE plus venetoclax poised to become first all-oral fixed-duration regimen of a second-generation BTK inhibitor plus venetoclax in 1st-line CLL. WILMINGTON, Del., December 08, 2024----Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE  in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival  compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia .Both investigational arms demonstrated durable responses, with estimated 36-month PFS rates of 76.5% for CALQUENCE plus venetoclax and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/usNgcZHCkTNCwRfSrRhYiQ--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/00ecf8619a060c319ac3ba209f6673b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/usNgcZHCkTNCwRfSrRhYiQ--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/00ecf8619a060c319ac3ba209f6673b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fixed-duration-calquence-plus-venetoclax-160000602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2462157665.USD","LU1829250122.USD","LU0889565916.HKD","LU0109394709.USD","BK4568","AZN","LU2463526074.USD","PFS","BK4109","LU2456880835.USD","BK4585","LU2236285917.USD","OS","BK4097","LU2417539215.USD","PML","BK4211","III","BK4007","BK4588","LU0320765992.SGD","TLS","ASH","BK4195","BK4134"],"gpt_icon":0},{"id":"2488306954","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2488306954","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488306954?lang=en_us&edition=fundamental","pubTime":"2024-12-03 06:28","pubTimestamp":1733178480,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of October 31, 2024:. Annualized current distribution rate expressed as a percentage of NAV as of 10/31/2024. Annualized current distribution rate expressed as a percentage of Market Price as of 10/31/2024","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tDL6rJUq.2vVNfZYoL5wbA--~B/aD0yMjt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/da/globenewswire.com/643702798dbfb61cffe8eced7add6163","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tDL6rJUq.2vVNfZYoL5wbA--~B/aD0yMjt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/da/globenewswire.com/643702798dbfb61cffe8eced7add6163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-222800345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFL","PMF","PYN","PAXS","PDO","PDX","PCN","PNF","PTY","PML","PNI","PHK","PGP","PDI","PCQ","PZC","RCS","PCK","PFN","PCM","PMX"],"gpt_icon":0},{"id":"2484154512","title":"Australian Prudential Regulator's Reinsurance Reforms Could Benefit Insurers over the Medium Term, Fitch Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2484154512","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484154512?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:57","pubTimestamp":1732085874,"startTime":"0","endTime":"0","summary":"Australia's prudential regulator's proposed changes to reinsurance-related capital requirements could help improve Australian insurers' credit profiles in the medium term if they enhance access to reinsurance protection, Fitch Ratings said in a Tuesday release.However, their financial stability over the long term will depend on insurers' willingness to take on reinsurance, amid external factors like catastrophe reinsurance pricing and the frequency, severity, and cost of natural disasters, the release said.Fitch believes regulatory adjustments alone may be insufficient to reduce reinsurance costs if catastrophe losses borne by reinsurers continue to escalate.The Australian Prudential Regulation Authority regulatory changes might have a limited effect on insurers' retention rates due to insurers' internal risk appetite and rating agency capital requirement.The availability of more reinsurance options will allow insurers to manage their net exposure to catastrophic risks without needing ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SUN.AU","XAO.AU","IAG.AU","BK7034","QBE.AU","PML","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2483332212","title":"AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332212","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483332212?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:00","pubTimestamp":1731618000,"startTime":"0","endTime":"0","summary":"MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA asthe First Potential Treatment tor IgG4-RD. Phase 4 AGILE Data Support Shortening KRYSTEXXA Infusion Time. THOUSAND OAKS, Calif., Nov. 14, 2024 /PRNewswire/ -- Amgen  today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology  Convergence 2024 conference in Washington, D.C., Nov. 14-19, 2024. New data showcase reduction in disease activityby UPLIZNA  in Immunoglobulin G4-Related Disease  and support shorter infusion times for KRYSTEXXA co-administered with weekly oral methotrexate 15 mg.\"These data add to the growing body of evidence for UPLIZNA and KRYSTEXXA and strengthen our commitment to developing new treatment options for rare diseases like IgG4-RD and uncontrolled gout,\" said Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen. \"Patients living with these debilitating conditions dese","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-presents-data-across-rare-210000210.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-presents-data-across-rare-210000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B4R5TH58.HKD","BK4139","AMGN","ACR","BK4110","IE0002141913.USD","IE00B2B36J28.USD","PML","LU2242652126.USD","BK4534","BK4566","LU1061106388.HKD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4533","LU1057294990.SGD","RARE","LU0868494617.USD","BK4588","LU2112291526.USD","LU1983299246.USD","BK4585","LU0122379950.USD","LU0889565916.HKD","LU2242646821.SGD","BK4581","LU1571399168.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","SG9999001440.SGD","LU0320765992.SGD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2481905134","title":"AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481905134","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481905134?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"First results from AMPLIFY trial will reinforce CALQUENCE as leading second-generation BTK inhibitor in frontline chronic lymphocytic leukemia with fixed-duration regimen. Next generation cell therapy and T-cell engagers will demonstrate promising early results in multiple types of blood cancer. WILMINGTON, Del., November 07, 2024----AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society of Hematology  Annual Meeting and Exposition December 7-10, 2024.Christophe Hotermans, Senior Vice President, Head of Global Medical Affairs, Alexion, said: \"Our ASH presentations will highlight the transformative impact of our medicines, including new analyses from the ALPHA Phase III trial reaffirming the safety and efficacy of our first-in-class Factor D inhibitor, VOYDEYA as add-on to ULTOMIRIS or SOLIRIS for the subset of patients with PNH experiencing clinically significant extravascular h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sxTLZDXjyixVo0t2ymPKmA--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5be4b70c947690ffb1d01c948a0a8945","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sxTLZDXjyixVo0t2ymPKmA--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5be4b70c947690ffb1d01c948a0a8945"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-showcases-strength-hematology-portfolio-120000651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z6F94.USD","LU2417539215.USD","IE0031619046.USD","BK4167","BK4561","EVH","LU2236285917.USD","BK4560","LU2463526074.USD","PST","LU0109394709.USD","LU0170899867.USD","BK4588","BK4007","BK4539","LU0320765992.SGD","BK4585","ASH","LU2286300806.USD","LU2346227817.USD","IE00B66KJ199.SGD","AL","LU2456880835.USD","IE00B19Z4B17.USD","LU2462157665.USD","S","ED","BK4109","LU0889565916.HKD","BK4572","PML","IE0034390439.USD","BK4104","AZN","BK4006","BK4097","LU1829250122.USD","CRS","IE00B7SZL793.SGD","BK4568","BK4208","LU0053671581.USD"],"gpt_icon":0},{"id":"2480326193","title":"PIMCO Municipal Income Fund II declares $0.0395 dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2480326193","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480326193?lang=en_us&edition=fundamental","pubTime":"2024-11-04 13:46","pubTimestamp":1730699191,"startTime":"0","endTime":"0","summary":"PIMCO Municipal Income Fund II (NYSE:PML) declares $0.0395/share monthly dividend, in line with previous.\n\nForward yield 5.37%\nPayable Dec. 2; for shareholders of record Nov. 12; ex-div Nov. 12.\nSee PML Dividend Scorecard, Yield Chart, & Dividend Growth.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4241120-pimco-municipal-income-fund-ii-declares-0_0395-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["US3Y.BOND","US10Y.BOND","US12M.BOND","US7Y.BOND","PML","US912797HE00.BOND","US6M.BOND","US2Y.BOND","US5Y.BOND","US30Y.BOND"],"gpt_icon":0},{"id":"2480850855","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2480850855","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480850855?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:34","pubTimestamp":1730493240,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of September 30, 2024:. Annualized current distribution rate expressed as a percentage of NAV as of 09/30/2024. Annualized current distribution rate expressed as a percentage of Market Price as of 09/30/2024","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/s05UsudlQafrnlghRT6v2w--~B/aD0yMjt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/643702798dbfb61cffe8eced7add6163","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/s05UsudlQafrnlghRT6v2w--~B/aD0yMjt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/643702798dbfb61cffe8eced7add6163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-203400113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFN","PMX","PDI","PML","PDX","PGP","PFL","PHK","PCK","PDO","PCN","PMF","PCQ","RCS","PYN","PNI","PZC","PNF","PCM","PTY","PAXS"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PML\",params:#limit:5,,,undefined,":[{"date":"2025-04-11","symbol":"PML","amount":0.0395,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-11","defaultRemindTime":1744378200000,"name":"太平洋投资管理市政收益基金2","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-01","payableDate":"2025-04-11","currency":"USD","dateTimestamp":1744344000000,"payDate":"2025-05-01"},{"date":"2025-03-13","symbol":"PML","amount":0.0395,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"太平洋投资管理市政收益基金2","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-04-01"},{"date":"2025-02-13","symbol":"PML","amount":0.0395,"announcedDate":"2025-02-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-13","defaultRemindTime":1739457000000,"name":"太平洋投资管理市政收益基金2","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739422800000,"payDate":"2025-03-03"},{"date":"2025-01-13","symbol":"PML","amount":0.0395,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-13","defaultRemindTime":1736778600000,"name":"太平洋投资管理市政收益基金2","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-03","payableDate":"2025-01-13","currency":"USD","dateTimestamp":1736744400000,"payDate":"2025-02-03"},{"date":"2024-12-12","symbol":"PML","amount":0.0395,"announcedDate":"2024-12-02","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"太平洋投资管理市政收益基金2","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-02","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2025-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PML\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-07","recordDate":"2015-05-11","paymentDate":"2015-06-01","value":0.065,"currency":"USD"},{"executeDate":"2015-06-09","recordDate":"2015-06-11","paymentDate":"2015-07-01","value":0.065,"currency":"USD"},{"executeDate":"2015-07-09","recordDate":"2015-07-13","paymentDate":"2015-08-03","value":0.065,"currency":"USD"},{"executeDate":"2015-08-11","recordDate":"2015-08-13","paymentDate":"2015-09-01","value":0.065,"currency":"USD"},{"executeDate":"2015-09-09","recordDate":"2015-09-11","paymentDate":"2015-10-01","value":0.065,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PML\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PML\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PML","date":"2025-04-25","current":764.185044,"percent":0.979691,"low":-4.583911,"twenty":-3.098642,"median":16.44332,"eighty":32.863033,"high":861.740581,"avg":37.784468,"sd":131.821916,"marketCap":499777019},"quantilePoints":[{"date":"2020-05-01","current":6.893153,"twenty":5.856953,"median":10.876061,"eighty":52.39183,"marketCap":760232073},{"date":"2020-05-08","current":7.103068,"twenty":5.861819,"median":10.876061,"eighty":52.39183,"marketCap":783383173},{"date":"2020-05-15","current":6.836419,"twenty":5.86664,"median":10.876061,"eighty":52.39183,"marketCap":753975019},{"date":"2020-05-22","current":7.023641,"twenty":5.877184,"median":10.876061,"eighty":52.39183,"marketCap":774623297},{"date":"2020-05-29","current":7.227882,"twenty":5.894349,"median":10.876061,"eighty":52.39183,"marketCap":797148692},{"date":"2020-06-05","current":7.443471,"twenty":5.905809,"median":10.876061,"eighty":52.39183,"marketCap":820925497},{"date":"2020-06-12","current":7.528571,"twenty":5.915389,"median":10.876061,"eighty":52.39183,"marketCap":830311079},{"date":"2020-06-19","current":7.517225,"twenty":5.920179,"median":10.876061,"eighty":52.39183,"marketCap":829059668},{"date":"2020-06-26","current":7.625019,"twenty":5.947209,"median":10.876061,"eighty":52.39183,"marketCap":840948071},{"date":"2020-07-02","current":7.647712,"twenty":5.967557,"median":10.876061,"eighty":52.39183,"marketCap":843450892},{"date":"2020-07-10","current":7.74416,"twenty":6.032913,"median":10.876061,"eighty":52.39183,"marketCap":854087884},{"date":"2020-07-17","current":7.613672,"twenty":6.084813,"median":10.876061,"eighty":52.39183,"marketCap":839696660},{"date":"2020-07-24","current":7.676079,"twenty":6.11653,"median":10.876061,"eighty":52.39183,"marketCap":846579419},{"date":"2020-07-31","current":7.800893,"twenty":6.15978,"median":10.876061,"eighty":52.39183,"marketCap":860344938},{"date":"2020-08-07","current":7.976768,"twenty":6.511902,"median":10.876061,"eighty":52.39183,"marketCap":879741806},{"date":"2020-08-14","current":7.988115,"twenty":6.680969,"median":10.876061,"eighty":52.39183,"marketCap":880993217},{"date":"2020-08-21","current":7.84628,"twenty":6.772877,"median":10.876061,"eighty":52.39183,"marketCap":865350582},{"date":"2020-08-28","current":33.115673,"twenty":6.863651,"median":10.876061,"eighty":52.39183,"marketCap":836568133},{"date":"2020-09-04","current":33.041367,"twenty":6.924924,"median":10.892734,"eighty":52.39183,"marketCap":834691016},{"date":"2020-09-11","current":33.189979,"twenty":6.997543,"median":10.901414,"eighty":52.39183,"marketCap":838445249},{"date":"2020-09-18","current":32.99183,"twenty":7.055911,"median":10.908463,"eighty":52.39183,"marketCap":833439606},{"date":"2020-09-25","current":32.867987,"twenty":7.103068,"median":10.916328,"eighty":52.39183,"marketCap":830311079},{"date":"2020-10-02","current":33.90827,"twenty":7.164908,"median":10.932058,"eighty":52.39183,"marketCap":856590706},{"date":"2020-10-09","current":33.660583,"twenty":7.226747,"median":10.952118,"eighty":52.39183,"marketCap":850333652},{"date":"2020-10-16","current":33.388128,"twenty":7.292559,"median":10.971382,"eighty":52.39183,"marketCap":843450892},{"date":"2020-10-23","current":33.146634,"twenty":7.487723,"median":10.994976,"eighty":52.39183,"marketCap":837350264},{"date":"2020-10-30","current":32.6203,"twenty":7.517225,"median":11.010706,"eighty":52.39183,"marketCap":824054024},{"date":"2020-11-06","current":34.122915,"twenty":7.543322,"median":11.028174,"eighty":52.39183,"marketCap":862013083},{"date":"2020-11-13","current":34.34708,"twenty":7.583036,"median":11.05003,"eighty":52.39183,"marketCap":867675942},{"date":"2020-11-20","current":34.645967,"twenty":7.613672,"median":11.070428,"eighty":52.39183,"marketCap":875226422},{"date":"2020-11-27","current":35.293555,"twenty":7.623884,"median":11.09578,"eighty":52.39183,"marketCap":891585794},{"date":"2020-12-04","current":35.841515,"twenty":7.647712,"median":11.112681,"eighty":52.39183,"marketCap":905428340},{"date":"2020-12-11","current":36.115494,"twenty":7.738486,"median":11.121132,"eighty":52.39183,"marketCap":912349613},{"date":"2020-12-18","current":35.492813,"twenty":7.766853,"median":11.146484,"eighty":52.39183,"marketCap":896619447},{"date":"2020-12-24","current":35.642257,"twenty":7.826991,"median":11.163386,"eighty":52.39183,"marketCap":900394687},{"date":"2020-12-31","current":35.617349,"twenty":7.880321,"median":11.171836,"eighty":52.39183,"marketCap":899765480},{"date":"2021-01-08","current":35.243741,"twenty":7.976768,"median":11.188738,"eighty":52.39183,"marketCap":890327381},{"date":"2021-01-15","current":35.766793,"twenty":8.008539,"median":11.197188,"eighty":52.39183,"marketCap":903540720},{"date":"2021-01-22","current":36.140401,"twenty":8.260437,"median":11.21409,"eighty":52.39183,"marketCap":912978820},{"date":"2021-01-29","current":36.339659,"twenty":8.559991,"median":11.645132,"eighty":52.39183,"marketCap":918012473},{"date":"2021-02-05","current":37.111784,"twenty":8.559991,"median":11.645132,"eighty":52.39183,"marketCap":937517878},{"date":"2021-02-12","current":37.609928,"twenty":8.559991,"median":11.645132,"eighty":52.39183,"marketCap":950102011},{"date":"2021-02-19","current":37.086876,"twenty":8.559991,"median":11.645132,"eighty":52.39183,"marketCap":936888672},{"date":"2021-02-26","current":35.617349,"twenty":8.559991,"median":11.645132,"eighty":52.39183,"marketCap":899765480},{"date":"2021-03-05","current":21.38431,"twenty":8.558857,"median":11.961874,"eighty":52.400383,"marketCap":913922630},{"date":"2021-03-12","current":21.62723,"twenty":8.558857,"median":11.991586,"eighty":52.400383,"marketCap":924304539},{"date":"2021-03-19","current":21.612507,"twenty":8.558857,"median":12.038621,"eighty":52.400383,"marketCap":923675332},{"date":"2021-03-26","current":21.62723,"twenty":8.559991,"median":12.075275,"eighty":52.39183,"marketCap":924304539},{"date":"2021-04-01","current":22.024735,"twenty":8.559991,"median":12.104034,"eighty":52.39183,"marketCap":941293118},{"date":"2021-04-09","current":21.789176,"twenty":8.558857,"median":12.147291,"eighty":52.400383,"marketCap":931225812},{"date":"2021-04-16","current":21.906956,"twenty":8.558857,"median":12.183725,"eighty":52.400383,"marketCap":936259465},{"date":"2021-04-23","current":21.906956,"twenty":8.558857,"median":12.198412,"eighty":52.400383,"marketCap":936259465},{"date":"2021-04-30","current":21.892233,"twenty":8.559991,"median":12.214142,"eighty":52.39183,"marketCap":935630258},{"date":"2021-05-07","current":22.05418,"twenty":8.559991,"median":12.222007,"eighty":52.39183,"marketCap":942551531},{"date":"2021-05-14","current":21.480005,"twenty":8.559991,"median":12.229872,"eighty":52.39183,"marketCap":918012473},{"date":"2021-05-21","current":21.494728,"twenty":8.559991,"median":12.23169,"eighty":52.39183,"marketCap":918641679},{"date":"2021-05-28","current":21.612507,"twenty":8.559991,"median":12.237737,"eighty":52.39183,"marketCap":923675332},{"date":"2021-06-04","current":21.862788,"twenty":8.559991,"median":12.247332,"eighty":52.39183,"marketCap":934371845},{"date":"2021-06-11","current":21.700842,"twenty":8.559991,"median":12.270794,"eighty":52.39183,"marketCap":927450572},{"date":"2021-06-18","current":21.715564,"twenty":8.559991,"median":12.284926,"eighty":52.39183,"marketCap":928079779},{"date":"2021-06-25","current":21.906956,"twenty":8.561126,"median":12.300656,"eighty":52.383278,"marketCap":936259465},{"date":"2021-07-02","current":22.304461,"twenty":8.561126,"median":12.316385,"eighty":52.383278,"marketCap":953248044},{"date":"2021-07-09","current":22.348628,"twenty":8.561126,"median":12.328827,"eighty":52.383278,"marketCap":955135664},{"date":"2021-07-16","current":22.083625,"twenty":8.561126,"median":12.367998,"eighty":52.383278,"marketCap":943809945},{"date":"2021-07-23","current":22.186681,"twenty":8.561126,"median":12.398967,"eighty":52.383278,"marketCap":948214391},{"date":"2021-07-30","current":22.289738,"twenty":8.561126,"median":12.45038,"eighty":52.383278,"marketCap":952618837},{"date":"2021-08-06","current":22.245571,"twenty":8.561126,"median":12.477841,"eighty":52.383278,"marketCap":950731217},{"date":"2021-08-13","current":22.127792,"twenty":8.561126,"median":12.513238,"eighty":52.383278,"marketCap":945697564},{"date":"2021-08-20","current":22.127792,"twenty":8.561126,"median":12.548405,"eighty":52.383278,"marketCap":945697564},{"date":"2021-08-27","current":22.230849,"twenty":8.561126,"median":21.387991,"eighty":52.383278,"marketCap":950102011},{"date":"2021-09-03","current":10.976404,"twenty":8.579281,"median":21.406393,"eighty":49.553144,"marketCap":945068358},{"date":"2021-09-10","current":10.925249,"twenty":8.579281,"median":21.406393,"eighty":49.553144,"marketCap":940663911},{"date":"2021-09-17","current":10.939864,"twenty":8.579281,"median":21.406393,"eighty":49.553144,"marketCap":941922325},{"date":"2021-09-24","current":10.888709,"twenty":8.579281,"median":21.406393,"eighty":49.553144,"marketCap":937517878},{"date":"2021-10-01","current":10.74986,"twenty":8.579281,"median":21.406393,"eighty":49.553144,"marketCap":925562952},{"date":"2021-10-08","current":10.64755,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":916754059},{"date":"2021-10-15","current":10.574471,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":910461993},{"date":"2021-10-22","current":10.34062,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":890327381},{"date":"2021-10-29","current":10.128692,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":872080389},{"date":"2021-11-05","current":10.428314,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":897877861},{"date":"2021-11-12","current":10.347928,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":890956588},{"date":"2021-11-19","current":10.516009,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":905428340},{"date":"2021-11-26","current":10.413699,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":896619447},{"date":"2021-12-03","current":10.516009,"twenty":8.597436,"median":21.399032,"eighty":46.72301,"marketCap":905428340},{"date":"2021-12-10","current":10.74986,"twenty":8.61559,"median":21.391671,"eighty":43.892877,"marketCap":925562952},{"date":"2021-12-17","current":10.713321,"twenty":8.61559,"median":21.391671,"eighty":43.892877,"marketCap":922416919},{"date":"2021-12-23","current":10.662166,"twenty":8.61559,"median":21.391671,"eighty":43.892877,"marketCap":918012473},{"date":"2021-12-31","current":10.676781,"twenty":8.61559,"median":21.391671,"eighty":43.892877,"marketCap":919270886},{"date":"2022-01-07","current":10.537932,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":907315960},{"date":"2022-01-14","current":10.377159,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":893473414},{"date":"2022-01-21","current":9.909456,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":853204190},{"date":"2022-01-28","current":9.872917,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":850058157},{"date":"2022-02-04","current":10.026382,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":863271496},{"date":"2022-02-11","current":9.945996,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":856350223},{"date":"2022-02-18","current":9.865609,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":849428950},{"date":"2022-02-25","current":9.500216,"twenty":8.633745,"median":21.391671,"eighty":41.062743,"marketCap":817968619},{"date":"2022-03-04","current":9.492908,"twenty":8.633745,"median":12.564128,"eighty":37.590002,"marketCap":817339412},{"date":"2022-03-11","current":18.722667,"twenty":8.633745,"median":12.564128,"eighty":37.091858,"marketCap":772665741},{"date":"2022-03-18","current":17.960343,"twenty":8.633745,"median":12.564128,"eighty":36.558843,"marketCap":741205410},{"date":"2022-03-25","current":17.076048,"twenty":8.633745,"median":12.564128,"eighty":36.314752,"marketCap":704711425},{"date":"2022-04-01","current":17.472456,"twenty":8.633745,"median":12.564128,"eighty":36.220104,"marketCap":721070797},{"date":"2022-04-08","current":16.877844,"twenty":8.633745,"median":12.564128,"eighty":36.090587,"marketCap":696531739},{"date":"2022-04-14","current":16.16126,"twenty":8.633745,"median":12.564128,"eighty":35.801663,"marketCap":666959027},{"date":"2022-04-22","current":16.298478,"twenty":8.633745,"median":12.564128,"eighty":35.667164,"marketCap":672621887},{"date":"2022-04-29","current":16.527175,"twenty":8.633745,"median":12.564128,"eighty":35.622331,"marketCap":682059986},{"date":"2022-05-06","current":16.450943,"twenty":8.633745,"median":12.564128,"eighty":35.502776,"marketCap":678913953},{"date":"2022-05-13","current":16.511929,"twenty":8.633745,"median":12.564128,"eighty":35.403147,"marketCap":681430780},{"date":"2022-05-20","current":15.841084,"twenty":8.633745,"median":12.564128,"eighty":35.293555,"marketCap":653745688},{"date":"2022-05-27","current":17.609675,"twenty":8.633745,"median":12.564128,"eighty":35.218834,"marketCap":726733657},{"date":"2022-06-03","current":17.899357,"twenty":8.633745,"median":12.564128,"eighty":34.79541,"marketCap":738688583},{"date":"2022-06-10","current":17.030309,"twenty":8.633745,"median":12.564128,"eighty":34.45169,"marketCap":702823805},{"date":"2022-06-17","current":15.459922,"twenty":8.633745,"median":12.564128,"eighty":34.222544,"marketCap":638015522},{"date":"2022-06-24","current":15.947809,"twenty":8.61559,"median":12.560196,"eighty":33.808021,"marketCap":658150134},{"date":"2022-07-01","current":16.801612,"twenty":8.61559,"median":12.560196,"eighty":33.645722,"marketCap":693385706},{"date":"2022-07-08","current":16.832104,"twenty":8.61559,"median":12.560196,"eighty":33.53674,"marketCap":694644119},{"date":"2022-07-15","current":17.106541,"twenty":8.61559,"median":12.560196,"eighty":33.415429,"marketCap":705969838},{"date":"2022-07-22","current":17.228513,"twenty":8.61559,"median":12.560196,"eighty":33.313822,"marketCap":711003491},{"date":"2022-07-29","current":17.914604,"twenty":8.61559,"median":12.560196,"eighty":33.128057,"marketCap":739317790},{"date":"2022-08-05","current":18.311012,"twenty":8.61559,"median":12.560196,"eighty":33.041367,"marketCap":755677162},{"date":"2022-08-12","current":18.500635,"twenty":8.61559,"median":12.560196,"eighty":32.871813,"marketCap":763502695},{"date":"2022-08-19","current":17.546359,"twenty":8.61559,"median":12.560196,"eighty":32.714421,"marketCap":724120692},{"date":"2022-08-26","current":17.192354,"twenty":8.61559,"median":12.560196,"eighty":32.598749,"marketCap":709511240},{"date":"2022-09-02","current":-4.583911,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":687279464},{"date":"2022-09-09","current":-4.528836,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":679021947},{"date":"2022-09-16","current":-4.295827,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":644086300},{"date":"2022-09-23","current":-4.244989,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":636463977},{"date":"2022-09-30","current":-4.0374,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":605339491},{"date":"2022-10-07","current":-4.181442,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":626936073},{"date":"2022-10-14","current":-4.054346,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":607880265},{"date":"2022-10-21","current":-3.897595,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":584378102},{"date":"2022-10-28","current":-3.795919,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":569133456},{"date":"2022-11-04","current":-3.634931,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":544996100},{"date":"2022-11-11","current":-3.829811,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":574215005},{"date":"2022-11-18","current":-3.918778,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":587554070},{"date":"2022-11-25","current":-4.0374,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":605339491},{"date":"2022-12-02","current":-4.054346,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":607880265},{"date":"2022-12-09","current":-4.016217,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":602163523},{"date":"2022-12-16","current":-4.007744,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":600893136},{"date":"2022-12-23","current":-3.897595,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":584378102},{"date":"2022-12-30","current":-3.829811,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":574215005},{"date":"2023-01-06","current":-3.872954,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":580683631},{"date":"2023-01-13","current":-3.967207,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":594815312},{"date":"2023-01-20","current":-4.078598,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":611516390},{"date":"2023-01-27","current":-4.074313,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":610874041},{"date":"2023-02-03","current":-4.112872,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":616655184},{"date":"2023-02-10","current":-4.035755,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":605092899},{"date":"2023-02-17","current":-3.945786,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":591603567},{"date":"2023-02-24","current":-3.902944,"twenty":9.492908,"median":15.459922,"eighty":32.598749,"marketCap":585180075},{"date":"2023-03-03","current":-3.881523,"twenty":9.13262,"median":15.459922,"eighty":32.598749,"marketCap":581968329},{"date":"2023-03-10","current":-3.231032,"twenty":8.493045,"median":15.459922,"eighty":32.598749,"marketCap":580041282},{"date":"2023-03-17","current":-3.263235,"twenty":8.014212,"median":15.459922,"eighty":32.598749,"marketCap":585822424},{"date":"2023-03-24","current":-3.191673,"twenty":7.976768,"median":15.459922,"eighty":32.598749,"marketCap":572975441},{"date":"2023-03-31","current":-3.359844,"twenty":7.917765,"median":15.444676,"eighty":32.59714,"marketCap":603165851},{"date":"2023-04-06","current":-3.356266,"twenty":7.838338,"median":15.444676,"eighty":32.59714,"marketCap":602523502},{"date":"2023-04-14","current":-3.345531,"twenty":7.766853,"median":15.459922,"eighty":32.598749,"marketCap":600596455},{"date":"2023-04-21","current":-3.227454,"twenty":7.738486,"median":15.459922,"eighty":32.598749,"marketCap":579398933},{"date":"2023-04-28","current":-3.259657,"twenty":7.647712,"median":15.459922,"eighty":32.598749,"marketCap":585180075},{"date":"2023-05-05","current":-3.263235,"twenty":7.622749,"median":15.459922,"eighty":32.598749,"marketCap":585822424},{"date":"2023-05-12","current":-3.231032,"twenty":7.611403,"median":15.459922,"eighty":32.598749,"marketCap":580041282},{"date":"2023-05-19","current":-3.245344,"twenty":7.571689,"median":15.459922,"eighty":32.598749,"marketCap":582610679},{"date":"2023-05-26","current":-3.15947,"twenty":7.534245,"median":15.459922,"eighty":32.598749,"marketCap":567194299},{"date":"2023-06-02","current":-3.241766,"twenty":7.517225,"median":15.459922,"eighty":32.598749,"marketCap":581968329},{"date":"2023-06-09","current":-3.284703,"twenty":7.486588,"median":15.459922,"eighty":32.598749,"marketCap":589676519},{"date":"2023-06-16","current":-3.213141,"twenty":7.289155,"median":15.459922,"eighty":32.598749,"marketCap":576829536},{"date":"2023-06-23","current":-3.205985,"twenty":7.239229,"median":15.505662,"eighty":32.600357,"marketCap":575544838},{"date":"2023-06-30","current":-3.238188,"twenty":7.182495,"median":15.559024,"eighty":32.603574,"marketCap":581325980},{"date":"2023-07-07","current":-3.213141,"twenty":7.148455,"median":15.559024,"eighty":32.603574,"marketCap":576829536},{"date":"2023-07-14","current":-3.327641,"twenty":7.091721,"median":15.559024,"eighty":32.603574,"marketCap":597384709},{"date":"2023-07-21","current":-3.270391,"twenty":7.046334,"median":15.559024,"eighty":32.603574,"marketCap":587107123},{"date":"2023-07-28","current":-3.281125,"twenty":6.983927,"median":15.559024,"eighty":32.603574,"marketCap":589034170},{"date":"2023-08-04","current":-3.191673,"twenty":6.876133,"median":15.559024,"eighty":32.603574,"marketCap":572975441},{"date":"2023-08-11","current":-3.180938,"twenty":6.825073,"median":15.559024,"eighty":32.603574,"marketCap":571048394},{"date":"2023-08-18","current":-3.166626,"twenty":6.745645,"median":15.559024,"eighty":32.603574,"marketCap":568478997},{"date":"2023-08-25","current":-3.10222,"twenty":6.620831,"median":15.559024,"eighty":32.603574,"marketCap":556916713},{"date":"2023-09-01","current":-3.105798,"twenty":6.110227,"median":12.571932,"eighty":32.603574,"marketCap":557559062},{"date":"2023-09-08","current":36.32369,"twenty":5.730111,"median":12.556269,"eighty":32.645069,"marketCap":554989665},{"date":"2023-09-15","current":34.894286,"twenty":5.730111,"median":12.556269,"eighty":32.843218,"marketCap":533149794},{"date":"2023-09-22","current":33.843253,"twenty":5.730111,"median":12.556269,"eighty":32.99183,"marketCap":517091065},{"date":"2023-09-29","current":32.077518,"twenty":5.730111,"median":12.556269,"eighty":32.99183,"marketCap":490112401},{"date":"2023-10-06","current":31.48894,"twenty":5.730111,"median":12.556269,"eighty":32.99183,"marketCap":481119513},{"date":"2023-10-13","current":31.236692,"twenty":5.730111,"median":12.556269,"eighty":32.99183,"marketCap":477265418},{"date":"2023-10-20","current":29.55504,"twenty":5.730111,"median":12.556269,"eighty":32.99183,"marketCap":451571452},{"date":"2023-10-27","current":29.428916,"twenty":0.443594,"median":12.544467,"eighty":33.021552,"marketCap":449644405},{"date":"2023-11-03","current":31.446899,"twenty":0.443594,"median":12.544467,"eighty":33.021552,"marketCap":480477164},{"date":"2023-11-10","current":33.427779,"twenty":0.443594,"median":12.544467,"eighty":33.105765,"marketCap":510743031},{"date":"2023-11-17","current":34.818792,"twenty":0.443594,"median":12.544467,"eighty":33.189979,"marketCap":531996317},{"date":"2023-11-24","current":34.775322,"twenty":0.443594,"median":12.544467,"eighty":33.313822,"marketCap":531332152},{"date":"2023-12-01","current":35.166545,"twenty":0.443594,"median":12.544467,"eighty":33.395614,"marketCap":537309638},{"date":"2023-12-08","current":35.775113,"twenty":2.205766,"median":12.548405,"eighty":33.523526,"marketCap":546607951},{"date":"2023-12-15","current":36.122866,"twenty":2.205766,"median":12.548405,"eighty":33.591231,"marketCap":551921272},{"date":"2023-12-22","current":36.42715,"twenty":2.205766,"median":12.548405,"eighty":33.695259,"marketCap":556570429},{"date":"2023-12-29","current":35.94899,"twenty":0.443594,"median":12.544467,"eighty":33.790413,"marketCap":549264612},{"date":"2024-01-05","current":36.383681,"twenty":-1.318579,"median":12.540584,"eighty":33.896498,"marketCap":555906264},{"date":"2024-01-12","current":36.035928,"twenty":-1.318579,"median":12.540584,"eighty":34.222544,"marketCap":550592942},{"date":"2024-01-19","current":35.296952,"twenty":-3.080751,"median":12.536701,"eighty":34.305708,"marketCap":539302134},{"date":"2024-01-26","current":35.644705,"twenty":-1.318579,"median":12.540584,"eighty":34.568587,"marketCap":544615455},{"date":"2024-02-02","current":37.296533,"twenty":-1.318579,"median":12.540584,"eighty":34.679901,"marketCap":569853733},{"date":"2024-02-09","current":37.166126,"twenty":-1.318579,"median":12.540584,"eighty":34.775322,"marketCap":567861237},{"date":"2024-02-16","current":37.340002,"twenty":-1.318579,"median":12.540584,"eighty":34.938367,"marketCap":570517898},{"date":"2024-02-23","current":37.47041,"twenty":-1.318579,"median":12.540584,"eighty":35.152095,"marketCap":572510393},{"date":"2024-03-01","current":37.166126,"twenty":0.443594,"median":12.544467,"eighty":35.218834,"marketCap":567861237},{"date":"2024-03-08","current":9.170549,"twenty":0.443594,"median":12.528737,"eighty":35.203579,"marketCap":565868741},{"date":"2024-03-15","current":8.944515,"twenty":0.443594,"median":12.505142,"eighty":34.9667,"marketCap":551921272},{"date":"2024-03-22","current":9.105968,"twenty":0.443594,"median":12.458493,"eighty":34.801404,"marketCap":561883750},{"date":"2024-03-28","current":9.095204,"twenty":0.443594,"median":12.442223,"eighty":34.740615,"marketCap":561219585},{"date":"2024-04-05","current":9.105968,"twenty":-1.318579,"median":12.391102,"eighty":34.594247,"marketCap":561883750},{"date":"2024-04-12","current":9.009096,"twenty":-1.318579,"median":12.348446,"eighty":34.338806,"marketCap":555906264},{"date":"2024-04-19","current":8.944515,"twenty":-1.318579,"median":12.32425,"eighty":34.222544,"marketCap":551921272},{"date":"2024-04-26","current":8.740007,"twenty":0.443594,"median":12.308521,"eighty":33.907338,"marketCap":539302134},{"date":"2024-05-03","current":8.858406,"twenty":0.443594,"median":12.292791,"eighty":33.758484,"marketCap":546607951},{"date":"2024-05-10","current":9.095204,"twenty":0.443594,"median":12.277061,"eighty":33.6414,"marketCap":561219585},{"date":"2024-05-17","current":8.987569,"twenty":0.443594,"median":12.253466,"eighty":33.53674,"marketCap":554577933},{"date":"2024-05-24","current":8.966042,"twenty":0.443594,"median":12.237737,"eighty":33.433711,"marketCap":553249603},{"date":"2024-05-31","current":9.084441,"twenty":0.443594,"median":12.23169,"eighty":33.354351,"marketCap":560555420},{"date":"2024-06-07","current":9.342766,"twenty":0.443594,"median":12.229872,"eighty":33.242744,"marketCap":576495384},{"date":"2024-06-14","current":9.235131,"twenty":-1.318579,"median":12.222007,"eighty":33.121931,"marketCap":569853733},{"date":"2024-06-21","current":9.149022,"twenty":-3.080751,"median":12.214142,"eighty":33.041367,"marketCap":564540411},{"date":"2024-06-28","current":9.181313,"twenty":-3.085045,"median":12.21021,"eighty":32.981922,"marketCap":566532907},{"date":"2024-07-05","current":9.224367,"twenty":-3.085045,"median":12.198412,"eighty":32.858079,"marketCap":569189567},{"date":"2024-07-12","current":9.235131,"twenty":-3.085045,"median":12.183725,"eighty":32.684699,"marketCap":569853733},{"date":"2024-07-15","current":9.299712,"twenty":-3.085045,"median":12.179814,"eighty":32.65993,"marketCap":573838724},{"date":"2024-08-02","current":9.310475,"twenty":-3.098642,"median":12.137841,"eighty":32.077518,"marketCap":574502889},{"date":"2024-08-09","current":9.267421,"twenty":-3.098642,"median":12.088304,"eighty":31.446899,"marketCap":571846228},{"date":"2024-08-16","current":9.256658,"twenty":-3.098642,"median":12.043992,"eighty":30.71538,"marketCap":571182063},{"date":"2024-08-23","current":9.299712,"twenty":-3.098642,"median":11.993926,"eighty":29.588673,"marketCap":573838724},{"date":"2024-08-30","current":9.525747,"twenty":-3.098642,"median":11.973605,"eighty":29.395282,"marketCap":587786193},{"date":"2024-09-06","current":9.568801,"twenty":-3.098642,"median":11.699878,"eighty":29.395282,"marketCap":590442853},{"date":"2024-09-13","current":9.923998,"twenty":-3.098642,"median":11.005635,"eighty":29.395282,"marketCap":612360305},{"date":"2024-09-20","current":9.913235,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":611696139},{"date":"2024-09-27","current":25.615339,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":612360305},{"date":"2024-10-04","current":26.115422,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":624315278},{"date":"2024-10-11","current":25.615339,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":612360305},{"date":"2024-10-18","current":25.782034,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":616345296},{"date":"2024-10-25","current":24.837433,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":593763679},{"date":"2024-10-31","current":24.754086,"twenty":-3.098642,"median":10.947172,"eighty":29.395282,"marketCap":591771184},{"date":"2024-11-08","current":24.909186,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":595479001},{"date":"2024-11-15","current":24.408778,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":583516253},{"date":"2024-11-22","current":23.797169,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":568895117},{"date":"2024-11-29","current":24.686783,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":590162224},{"date":"2024-12-06","current":24.353177,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":582187059},{"date":"2024-12-13","current":23.685967,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":566236729},{"date":"2024-12-20","current":22.323746,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":533671471},{"date":"2024-12-27","current":22.379347,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":535000665},{"date":"2025-01-03","current":22.740752,"twenty":-3.098642,"median":10.943518,"eighty":29.403691,"marketCap":543640427},{"date":"2025-01-10","current":22.935355,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":548292607},{"date":"2025-01-17","current":22.629551,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":540982039},{"date":"2025-01-24","current":22.824154,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":545634219},{"date":"2025-01-31","current":23.352362,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":558261564},{"date":"2025-02-07","current":23.85277,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":570224311},{"date":"2025-02-14","current":23.352362,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":558261564},{"date":"2025-02-21","current":23.658167,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":565572132},{"date":"2025-02-28","current":23.908371,"twenty":-3.098642,"median":10.939864,"eighty":29.412099,"marketCap":571553506},{"date":"2025-03-07","current":861.740581,"twenty":-3.098642,"median":11.001981,"eighty":29.428916,"marketCap":563578340},{"date":"2025-03-14","current":834.303087,"twenty":-3.098642,"median":15.505662,"eighty":30.303375,"marketCap":545634219},{"date":"2025-03-21","current":827.189662,"twenty":-3.098642,"median":15.833461,"eighty":31.404858,"marketCap":540982039},{"date":"2025-03-28","current":817.027627,"twenty":-3.098642,"median":15.955433,"eighty":31.690738,"marketCap":534336068},{"date":"2025-04-04","current":826.173459,"twenty":-3.098642,"median":16.184129,"eighty":32.2625,"marketCap":540317442},{"date":"2025-04-11","current":745.893381,"twenty":-3.098642,"median":16.298478,"eighty":32.61361,"marketCap":487814271},{"date":"2025-04-17","current":760.120229,"twenty":-3.098642,"median":16.37471,"eighty":32.684699,"marketCap":497118630},{"date":"2025-04-25","current":764.185044,"twenty":-3.098642,"median":16.44332,"eighty":32.863033,"marketCap":499777019}],"updateTime":1745735855494}}}